Emergent BioSolutions (EBS) Tops Q3 EPS by $1.27
Tweet
Share
E-mailGet Alerts EBS Hot Sheet
Price: $8.00 -1.72%
Revenue Growth %: +32.0%
Financial Fact:
Interest income: 358K
Today's EPS Names:
DTGI, CRMT, MAYS, More
Revenue Growth %: +32.0%
Financial Fact:
Interest income: 358K
Today's EPS Names:
DTGI, CRMT, MAYS, More
Join SI Premium – FREE
Emergent BioSolutions (NYSE: EBS) reported Q3 EPS of $1.37, $1.27 better than the analyst estimate of $0.10. Revenue for the quarter came in at $293.8 million versus the consensus estimate of $290.33 million.
GUIDANCE:
Emergent BioSolutions sees FY2024 revenue of $1.065-1.125 billion.
For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Kalshi in early talks for IPO - The Information
- Air France-KLM (AF:FP) (AFLYY) PT Raised to EUR13.50 at UBS
- Iran Says Hormuz To Close, Citing Ceasefire Violation- Tasnim
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
